Trial ID: | L7209 |
Source ID: | NCT06132477
|
Associated Drug: |
Glp-1 Receptor Agonist
|
Title: |
Impact GLP-1 Agonists Following Bariatric
|
Acronym: |
|
Status: |
RECRUITING
|
Study Results: |
NO
|
Results: |
|
Conditions: |
Morbid Obesity|Metabolic Syndrome|Diabetes Mellitus|Hypertension|Obstructive Sleep Apnea of Adult
|
Interventions: |
DRUG: GLP-1 receptor agonist
|
Outcome Measures: |
Primary: Effect of GLP1-RA on weight loss, To investigate the effects of GLP1-RAs on weight loss reflected as change in BMI (kg per meter sq) in patients undergoing metabolic surgery, 6 months|Effect of GLP1-RA on circulating bile acids and metabolites, Determine the impact of GLP1-RA on circulating bile acids and other metabolites, 6 months|Effector of GLP1-RA on gut microbiome diversity, To determine the impact of GLP1-RAs after bariatric surgery on changes in the gut microbiome, 6 months|Effect of GLP1-RA on satiety and hunger, To assess the impact of GLP-1 agonists on satiety and hunger in patients who undergo metabolic surgery. Scale will be a validated scoring system, "Daily Eats Questionnaire," with scores ranging from 0-10, with a 0 indicating no hunger, and 10 indicating extreme hunger, 6 months|Effect of GLP1-RA on Glycemic control, HGBA1C levels will be measured at 3 and 6 months after surgery to determine if HGBA1C drops more in patients maintained on GLP1-RA, 6 months |
|
Sponsor/Collaborators: |
Sponsor: University of Missouri-Columbia | Collaborators: American Society for Metabolic and Bariatric Surgery
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE4
|
Enrollment: |
150
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
Start Date: |
2024-02-01
|
Completion Date: |
2028-07
|
Results First Posted: |
|
Last Update Posted: |
2024-09-20
|
Locations: |
University of Missouri Hospital, Columbia, Missouri, 65201, United States
|
URL: |
https://clinicaltrials.gov/show/NCT06132477
|